On May 4, 2026, the Scientific Committee on Consumer Safety (SCCS)— the premier scientific and advisory body of the European Union for consumer safety — officially received a mandate from the European Commission to thoroughly reassess the safety of a widely used fragrance ingredient – Hydroxycitronellal. This mandate, which was approved by written procedure on April 30, 2026, initiates a comprehensive 12-month review process that could completely reshape how the beauty industry manages its product scent profiles.

Here is an in-depth dive into the recent SCCS mandate, the underlying science of skin sensitization risk assessment, and exactly what this critical reassessment means for the regulation of fragrance allergens moving forward.

What is Hydroxycitronellal and Why is it Under the Spotlight?

Hydroxycitronellal (chemically known as 7-hydroxy-3,7-dimethyloctanal, CAS No. 107-75-5) is an immensely popular fragrance ingredient celebrated throughout the industry for its highly desirable, pleasant floral odor profile. Because of its appealing scent, you will find it utilized across a massive array of consumer goods, ranging from high-end perfumes and daily cosmetic lotions to various household and air care products.

However, despite its widespread popularity, Hydroxycitronellal is a well-known and documented skin sensitizer. This means that prolonged or repeated exposure can trigger skin sensitization, ultimately leading to Allergic Contact Dermatitis (ACD), which is a significant health concern for consumers exposed to scented products. Consequently, it is heavily regulated as one of the key fragrance allergens under the European Union Cosmetics Regulation (EC) No. 1223/2009. Under current regulations, it is formally listed in Annex III, entry 72. To maintain basic cosmetic compliance, cosmetic brands are legally mandated to explicitly declare it on their product’s INCI (International Nomenclature of Cosmetic Ingredients) list if its concentration exceeds specific safety thresholds:

• 10 ppm (0.001 %) in leave-on products (such as face lotions and skin creams).
• 100 ppm (0.01 %) in rinse-off products (such as shampoos, conditioners, and body washes).

Furthermore, under general Annex III entry 72 provisions, its maximum allowable concentration in finished cosmetic products (excluding oral care products) is capped at 1.0 %.

The Heart of the Mandate: The QRA2 Methodology

The focal point of this new European Commission mandate involves the critical evaluation of a submitted safety dossier that attempts to establish safe upper concentration limits using an advanced assessment procedure known as the QRA2 (Quantitative Risk Assessment 2) methodology.

For fragrance allergens, determining safety regarding skin sensitization departs from traditional substance-by-substance testing, instead aiming to firmly establish safe usage levels across multiple product types. Originally developed by the fragrance industry itself and subsequently undergoing substantial refinements following the International Dialogue for the Evaluation of Allergens (IDEA) project, the QRA methodology evaluates the precise risks of fragrances causing skin allergies. The updated QRA2 version is particularly notable because it incorporates vastly improved and enhanced exposure assessment models. Most importantly, it considers aggregate exposure—meaning it factors in the cumulative health risk of a consumer utilizing multiple different scented products simultaneously from various environmental sources.

The recently submitted dossier applies this exact QRA2 methodology to Hydroxycitronellal, deriving a “No Expected Sensitisation Induction Level” (NESIL) through a complex weight-of-evidence approach to propose safe use levels across various consumer product categories. The SCCS previously evaluated QRA2 in a case study focusing on Citral (which subsequently faced restrictions under Omnibus Act 2), finding that the derived safe use levels could be considered safe regarding the induction of skin sensitization. However, the committee also acknowledged that methodological limitations and scientific uncertainties remained. Because of these lingering uncertainties, the SCCS has historically insisted that the suitability of the QRA2 methodology must continue to be stringently assessed on a case-by-case basis.

Two Pivotal Questions for the SCCS

To provide regulatory clarity and protect public health, the European Commission has given the SCCS a strict 12-month deadline to thoroughly answer two pivotal questions outlined within their terms of reference:

1. Is Hydroxycitronellal Safe? In light of the provided data and taking into consideration the proposed upper safe levels derived via the QRA2 methodology, does the SCCS consider the ingredient safe regarding its sensitization potential at the maximum concentrations listed in the dossier submission?
2. Is QRA2 Reliable for the Wider Industry? Does the SCCS harbor any further scientific concerns regarding the use of the QRA2 methodology to derive safe upper concentration levels, not only for Hydroxycitronellal, but for fragrance allergens in general?

The Broader Impact on Cosmetic Compliance and Formulation

For regulatory affairs professionals, cosmetic chemists, and beauty brand owners, this specific piece of EU cosmetics regulation news is monumentally important. The questions posed by the European Commission undeniably extend far beyond the fate of a single floral ingredient.

If the SCCS ultimately concludes within the next year that QRA2 is a universally appropriate and scientifically robust methodology for establishing safe upper concentration limits, it will set a massive regulatory precedent for the entire beauty sector. It is highly probable that additional fragrance allergens will be subsequently reassessed using this aggregate exposure model. As seen with previous evaluations, this could eventually lead to new regulatory restrictions, drastically altered concentration limits, and intensive, costly reformulation efforts across the global cosmetics industry.

To proactively guarantee unwavering cosmetic compliance, brands must carefully and continuously monitor the outcome of this upcoming 12-month assessment. The final SCCS opinion will explicitly dictate the future formulation limits of Hydroxycitronellal, but more importantly, it could fundamentally and permanently shift how the European Union evaluates and regulates consumer fragrance safety for many years to come.

Read more on fragrance allergens here.